ClinicalTrials.gg
CompletedNCT06910059Updated Nov 6, 2026

The CT-verified Data Collection Study to Investigate the Correlation Between the Leadless Pacemaker Tip Location and Echo, ECG

An observational study in Bradycardia Sinus, AV Block and Atrial Fibrillation (AF), sponsored by Medtronic Cardiac Rhythm and Heart Failure. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Medtronic Cardiac Rhythm and Heart Failure (part of Medtronic) · Observational

How we know

Updated Nov 6, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
41
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies in Atrioventricular Block with a site in China — 5 open to participants now, 6 under way, none of them phase 3. Atrioventricular Block · China.

Started
2025
the only one that year
Observational
7 of 15
1 open now
Registered
13th of 15
by date
Lead sponsor
1 of 15
Medtronic Cardiac Rhythm and Heart Failure

Among the 15 studies in Atrioventricular Block with a site in China, this one is the only one that started in 2025, is one of 7 observational ones, and was the 13th registered.

Atrioventricular Block

118 studies on the registry are indexed under Atrioventricular Block; 44 are open to participants now.

Browse Atrioventricular Block studies →

Open to participants now

5 of the 15 studies in Atrioventricular Block with a site in China are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 29 Atrioventricular Block studies recruiting now, 21 (72%) set no upper age limit and 4 (14%) stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Atrioventricular Block with a site in China, or all of them as a file.
02

Study summary

The goal of this observational study is to assess inter-/intra- ventricular synchrony and ECG characteristics in relation to Micra tip location.

The secondary objective is (1) to identify an optimal Micra pacing location to improve LV function, (2) to investigate the correlation between Micra tip location and tricuspid regurgitation, and (3) to investigate whether Micra location would impact AV synchrony. Patients with pacing indications who plan to receive Micra AV implantation will be recruited.

03

Conditions studied

  • Bradycardia Sinus
  • AV Block
  • Atrial Fibrillation (AF)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

This study will enroll up to 40 subjects in site. Patients with pacing indications who plan to receive Micra AV implantation will be selected.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged above 18 years old
  • Patients who are willing to provide
  • Patients with Class I or II indications who plan to receive a leadless pacemaker, including SSS, AVB, AF with bradycardia, etc.
  • Patients who plan to conduct a cardiac CT scan after implantation

Exclusion criteria

Exclusion Criteria:

  • Patients with lead retention
  • Patients had heart valve replacement
  • Patients diagnosed with ischemic heart diseases
  • Patients who are allergic to or refuse to use contrast in CT scans
  • Patients who are pregnant or have a plan for pregnancy during the study
  • Patients with medical conditions that would limit study participation
  • Patients already enrolled in another clinical trial which would impact participation of this study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
41 participants (actual)
Patient registry
No

Interventions

  • OtherObservational

    It is a observational study and patients with pacing indications who plan to receive Micra AV implantation will be recruited. No intervention procedure will be performed.

06

What researchers measure

Primary outcomes

  1. Assessment of ECG characteristics in relation to Micra tip location

    Patients' ECG will be measured to see whether there is difference in ECG characteristics between Micra tip locations.

    Time frame: Within 6 months after the surgery.

Secondary outcomes

  1. Cardiac functional changes

    LVEF, RV length and quantity of tricuspid regurgitation will be measured.

    Time frame: Within 6 months after the surgery.

  2. To investigate whether Micra location would impact AV synchrony

    Percentage of AV synchrony will be measured.

    Time frame: Within 6 months after the surgery.

07

Study locations

1 site
08

References and documents

Publications

  • Reynolds D, Duray GZ, Omar R, Soejima K, Neuzil P, Zhang S, Narasimhan C, Steinwender C, Brugada J, Lloyd M, Roberts PR, Sagi V, Hummel J, Bongiorni MG, Knops RE, Ellis CR, Gornick CC, Bernabei MA, Laager V, Stromberg K, Williams ER, Hudnall JH, Ritter P; Micra Transcatheter Pacing Study Group. A Leadless Intracardiac Transcatheter Pacing System. N Engl J Med. 2016 Feb 11;374(6):533-41. doi: 10.1056/NEJMoa1511643. Epub 2015 Nov 9. PubMed 26551877 ↗
  • Udo EO, Zuithoff NP, van Hemel NM, de Cock CC, Hendriks T, Doevendans PA, Moons KG. Incidence and predictors of short- and long-term complications in pacemaker therapy: the FOLLOWPACE study. Heart Rhythm. 2012 May;9(5):728-35. doi: 10.1016/j.hrthm.2011.12.014. Epub 2011 Dec 17. PubMed 22182495 ↗
  • Kirkfeldt RE, Johansen JB, Nohr EA, Jorgensen OD, Nielsen JC. Complications after cardiac implantable electronic device implantations: an analysis of a complete, nationwide cohort in Denmark. Eur Heart J. 2014 May;35(18):1186-94. doi: 10.1093/eurheartj/eht511. Epub 2013 Dec 17. PubMed 24347317 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jun 2025 to primary completion in Jul 2026, 12 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Aug 2026 → Jul 2026 and completion Aug 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2025
First posted
Apr 4, 2025
StartActual
Jun 17, 2025
Primary completionActual
Jul 9, 2026was Aug 2026
CompletionActual
Sep 3, 2026was Aug 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 6, 2026
Primary completion
Aug 31, 2026→Jul 9, 2026 (actual)
Nov 6, 2026
Study completion
Aug 31, 2026→Sep 3, 2026 (actual)
Nov 6, 2026
Enrollment
40 (estimated)→41 (actual)
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Active, not recruiting→Completed
    Primary completion Aug 31, 2026→Jul 9, 2026 (now actual)
    Study completion Aug 31, 2026→Sep 3, 2026 (now actual)
    Enrollment 40 (estimated)→41 (actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06910059
Responsible party
Sponsor
First posted
Apr 4, 2025
Start date
Jun 17, 2025
Primary completion
Jul 9, 2026
Completion
Sep 3, 2026
Last update
Nov 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion